delivered via Vectura's dry powder inhaler. Hikma’s US subsidiary, West-Ward Pharmaceuticals, formerly Boehringer Ingelheim’s US generic business, Roxane, will be responsible for development.

Shares of Hikma Pharmaceuticals PLC HIK inched up 0.33% to £18.37 Monday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising 0.65% to ...

Hikma's filing for a generic version of ... for the fluticasone propionate and salmeterol inhalation powder – named VR 315 – will see Vectura receive $10 million for its part in the drug's ...

Shares of Hikma Pharmaceuticals PLC HIK rallied 1.64% to £18.01 Thursday, on what proved to be an all-around poor trading ...

London, United Kingdom – Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading.

Analyst Christian Glennie from Stifel Nicolaus reiterated a Buy rating on Hikma Pharmaceuticals (HIK – Research Report) and keeping the ...

Hikma Pharmaceuticals will acquire parts of Danish firm Xellia Pharmaceuticals, a drug company specialising in injectable ...

The company also reiterated guidance for its Branded business of revenue in the high-single digits, or 6% to 8% higher year-on-year, with a core operating margin around 25%. Its Generics business is ...